**Author details**

Rungrote Natesirinilkul Division of Hematology and Oncology, Department of Pediatrics, Faculty of Medicine, Chiang Mai University, Thailand

\*Address all correspondence to: rungrote.n@cmu.ac.th

© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**115**

*Thromboembolism in Beta-Thalassemia Disease DOI: http://dx.doi.org/10.5772/intechopen.89313*

[1] Viprakasit V, Origa R. Genetic basis, pathophysiology and diagnosis.

Porter J, Taher A, Viprakasit V, editors. Guidelines for the Management of Transfusion Dependent Thalassaemia (TDT). 3rd ed. Nicosia: Thalassaemia International Federation; 2014.

in the United States from 2001 to 2007.

Inati A. The hypercoagulable state in thalassemia intermedia. Hemoglobin.

[9] Eldor A, Rachmilewitz EA. The hypercoagulable state in thalassemia.

[10] Taher A, Isma'eel H, Mehio G, Bignamini D, Kattamis A, Rachmilewitz EA, et al. Prevalence of thromboembolic events among 8,860 patients with thalassaemia major and intermedia in the Mediterranean area and Iran. Thrombosis and Haemostasis. 2006;**96**:

[11] Borgna pignatti C, Carnelli V, Caruso V, Dore F, De Mattia D, Di Palma A, et al. Thromboembolic events in beta thalassemia major: An Italian multicenter study. Acta Haematologica.

[12] Sirachainan N. Thalassemia and the hypercoagulable state. Thrombosis

[13] Winichagoon P, Fucharoen S, Wasi P. Increased circulating platelet aggregates in thalassaemia. The Southeast Asian Journal of Tropical Medicine and Public Health.

[14] Eldor A, Krausz Y, Atlan H, Snyder D, Goldfarb A, Hy-Am E, et al. Platelet survival in patients with beta-thalassemia. American Journal of

Hematology. 1989;**32**:94-99

[15] Visudhiphan S, Ketsa-Ard K,

of blood coagulation and platelet profiles in relation to pulmonary thrombosis in beta-thalassemia/ Hb E. Southeast Asian Journal of

Tumliang S, Piankijagum A. Significance

Research. 2013;**132**:637-641

Pediatrics. 2009;**124**:1001-1008

[8] Taher AT, Musallam KM,

2009;**33**:160-169

488-491

1998;**99**:76-79

1981;**12**:556-560

Blood. 2002;**99**:36-43

[2] Viprakasit V, Ekwattanakit S. Clinical classification, screening and diagnosis

In: Cappellini MD, Cohen A,

for thalassemia. Hematology/ Oncology Clinics of North America.

[3] Taher A, Musallam K,

Cappellini MD. Guidelines for the Management of Non Transfusion Dependent Thalassaemia (NTDT). 2nd ed. Nicosia: Thalassaemia International

[4] Winichakoon P, Tantiworawit A, Rattanathammethee T, Hantrakool S, Chai-Adisaksopha C, Rattarittamrong E,

et al. Prevalence and risk factors for complications in patients with nontransfusion dependent alpha- and beta-thalassemia. Anemia. 2015;**2015**:793025. DOI:

[5] Teawtrakul N, Jetsrisuparb A,

Pongudom S, Sirijerachai C, Chansung K, Wanitpongpun C, et al. Epidemiologic study of major complications in adolescent and adult patients with thalassemia in Northeastern Thailand: The E-SAAN study phase I. Hematology.

[6] ISTH Steering Committee for World Thrombosis Day. Thrombosis: A major contributor to the global disease burden. Journal of Thrombosis and Haemostasis.

[7] Raffini L, Huang YS, Witmer C, Feudtner C. Dramatic increase in venous thromboembolism in children's hospitals

**References**

pp. 14-27

2018;**32**:193-211

Federation; 2017

10.1155/2015/793025

2018;**23**:55-60

2014;**12**:1580-1590

*Thromboembolism in Beta-Thalassemia Disease DOI: http://dx.doi.org/10.5772/intechopen.89313*
